A systematic review published in the Annals of the Rheumatic Diseases suggests, that biological agents used for the treatment of rheumatoid arthritis seem to be linked with an increased risk of skin cancer. Inflammatory arthritis has been associated with an increased risk of some types of cancers, in particular with lymphoma and lung cancer but with a lower risk of other cancer types, such as bowel and breast cancers.

Researchers set out to clarify whether tumor necrosis factor (TNF) inhibitors, i.e. drugs acting on the immune system, might affect the risk of cancer, by evaluating several clinical research databases, findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The findings were based on 21 studies and 8 conference abstracts, all complying to the strict inclusion criteria of reporting data on cancer linked to TNF inhibitors, including the monoclonal antibodies infliximab and adalimumab and the protein etanercept. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs.

The combined risk from seven studies for the development of any cancer revealed negligible or no increased risk, overall.

Two studies also showed no evidence of an increased cancer risk in patients taking TNF inhibitors over long-term, however, those previously diagnosed with cancer had a higher chance of being re-diagnosed with the disease, although this was not due to using TNF inhibitors.

Four studies revealed that patients treated with TNF inhibitors had a 45% higher chance of developing skin cancer other than melanoma, whereas two studies showed, that patients taking TNF inhibitors had a 79% increased risk of developing a melanoma compared with those who did not take these drugs.

The authors conclude:

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma. However, it does appear to increase the risk of skin cancer, including melanoma."


Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations

A systematic review published in the Annals of the Rheumatic Diseases suggests, that biological agents used for the treatment of rheumatoid arthritis seem to be linked with an increased risk of skin cancer. Inflammatory arthritis has been associated with an increased risk of some types of cancers, in particular with lymphoma and lung cancer but with a lower risk of other cancer types, such as bowel and breast cancers.

Researchers set out to clarify whether tumor necrosis factor (TNF) inhibitors, i.e. drugs acting on the immune system, might affect the risk of cancer, by evaluating several clinical research databases, findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The findings were based on 21 studies and 8 conference abstracts, all complying to the strict inclusion criteria of reporting data on cancer linked to TNF inhibitors, including the monoclonal antibodies infliximab and adalimumab and the protein etanercept. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs.

The combined risk from seven studies for the development of any cancer revealed negligible or no increased risk, overall.

Two studies also showed no evidence of an increased cancer risk in patients taking TNF inhibitors over long-term, however, those previously diagnosed with cancer had a higher chance of being re-diagnosed with the disease, although this was not due to using TNF inhibitors.

Four studies revealed that patients treated with TNF inhibitors had a 45% higher chance of developing skin cancer other than melanoma, whereas two studies showed, that patients taking TNF inhibitors had a 79% increased risk of developing a melanoma compared with those who did not take these drugs.

The authors conclude:

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma. However, it does appear to increase the risk of skin cancer, including melanoma."


Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations
When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle.. I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much. It's a beautiful painting but it's just too depressing to hang anywhere. I have a friend who collects these and I found one that depicts leopards and gave it to her for her birthday. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with us. Now we're very close.I have loved folk art paintings since I was a child. She looked so relaxed, that I could imagine what it felt like to lie there myself. I'll find someone to give it to. It's called First Trolley to Van Nuys and shows the center of a town filled with people. I saw a painting he did of a fishing scene but I chose not to buy it. I don't particularly care for his art. It was painted in 1988 by Reverend Howard Finster and is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van.....

The findings were based on 21 studies and 8 conference abstracts, all complying to the strict inclusion criteria of reporting data on cancer linked to TNF inhibitors, including the monoclonal antibodies infliximab and adalimumab and the protein etanercept.e. However, it does appear to increase the risk of skin cancer, including melanoma. The combined risk from seven studies for the development of any cancer revealed negligible or no increased risk, overall. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs. In total researchers It's of a swamp house on a bayou and has a Louisiana feel to it.One of my favorite paintings was done in 1962 by Bill Dodge. It's a beautiful painting but it's just too depressing to hang anywhere. It is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys.One of the most famous American artists is Thomas Chambers. Now we're very close.Another painting that I admire is called Howard in 1944. She looked so relaxed, that I could imagine what it felt like to lie there myself. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much. It's called First Trolley to Van Nuys and shows the center of a town filled with people. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with the boys and I used to tease her relentlessly and pull her pigtails whenever

ypes arthritis tpes arthritis tyes arthritis typs arthritis type arthritis types rthritis types athritis types arhritis types artritis types arthitis types arthrtis types arthriis types arthrits types arthriti rypes arthritis yypes arthritis ttpes arthritis tupes arthritis tyoes arthritis typws arthritis typrs arthritis typea arthritis typed arthritis types srthritis types aethritis types atthritis types arrhritis types aryhritis types artgritis types artjritis types artheitis types arthtitis types arthrutis types arthrotis types arthriris types arthriyis types arthritus types arthritos types arthritia types arthritid ytpes arthritis tpyes arthritis tyeps arthritis typse arthritis type sarthritis types rathritis types atrhritis types arhtritis types artrhitis types arthirtis types arthrtiis types arthriits types arthritsi types arthriti ttypes arthritis tyypes arthritis typpes arthritis typees arthritis typess arthritis types aarthritis types arrthritis types artthritis types arthhritis types arthrritis types arthriitis types arthrittis types arthritiis types arthritiss
A systematic review published in the Annals of the Rheumatic Diseases suggests, that biological agents used for the treatment of rheumatoid arthritis seem to be linked with an increased risk of skin cancer. Inflammatory arthritis has been associated with an increased risk of some types of cancers, in particular with lymphoma and lung cancer but with a lower risk of other cancer types, such as bowel and breast cancers.

Researchers set out to clarify whether tumor necrosis factor (TNF) inhibitors, i.e. drugs acting on the immune system, might affect the risk of cancer, by evaluating several clinical research databases, findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The findings were based on 21 studies and 8 conference abstracts, all complying to the strict inclusion criteria of reporting data on cancer linked to TNF inhibitors, including the monoclonal antibodies infliximab and adalimumab and the protein etanercept. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs.

The combined risk from seven studies for the development of any cancer revealed negligible or no increased risk, overall.

Two studies also showed no evidence of an increased cancer risk in patients taking TNF inhibitors over long-term, however, those previously diagnosed with cancer had a higher chance of being re-diagnosed with the disease, although this was not due to using TNF inhibitors.

Four studies revealed that patients treated with TNF inhibitors had a 45% higher chance of developing skin cancer other than melanoma, whereas two studies showed, that patients taking TNF inhibitors had a 79% increased risk of developing a melanoma compared with those who did not take these drugs.

The authors conclude:

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma. However, it does appear to increase the risk of skin cancer, including melanoma."


Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations

A systematic review published in the Annals of the Rheumatic Diseases suggests, that biological agents used for the treatment of rheumatoid arthritis seem to be linked with an increased risk of skin cancer. Inflammatory arthritis has been associated with an increased risk of some types of cancers, in particular with lymphoma and lung cancer but with a lower risk of other cancer types, such as bowel and breast cancers.

Researchers set out to clarify whether tumor necrosis factor (TNF) inhibitors, i.e. drugs acting on the immune system, might affect the risk of cancer, by evaluating several clinical research databases, findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The findings were based on 21 studies and 8 conference abstracts, all complying to the strict inclusion criteria of reporting data on cancer linked to TNF inhibitors, including the monoclonal antibodies infliximab and adalimumab and the protein etanercept. In total researchers collated information on over 40,000 patients and nearly 150,000 cumulative years of exposure to these drugs.

The combined risk from seven studies for the development of any cancer revealed negligible or no increased risk, overall.

Two studies also showed no evidence of an increased cancer risk in patients taking TNF inhibitors over long-term, however, those previously diagnosed with cancer had a higher chance of being re-diagnosed with the disease, although this was not due to using TNF inhibitors.

Four studies revealed that patients treated with TNF inhibitors had a 45% higher chance of developing skin cancer other than melanoma, whereas two studies showed, that patients taking TNF inhibitors had a 79% increased risk of developing a melanoma compared with those who did not take these drugs.

The authors conclude:

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma. However, it does appear to increase the risk of skin cancer, including melanoma."


Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations